Core Viewpoint - The company emphasizes the importance of standardizing capital market operations, improving corporate governance, and enhancing information disclosure and investor relations management [1] Group 1: Strategic Investment - The company will adhere to the principle of maximizing shareholder value when evaluating quality enterprises or resource targets for strategic investments [1] - It plans to conduct mergers and acquisitions at appropriate times to promote market resource integration and extend the industrial chain [1] Group 2: Internal Growth Focus - In the absence of clear investment opportunities, the company will concentrate on internal growth through technological innovation, business expansion, and management optimization [1] - This approach aims to solidify the company's development foundation and enhance its core competitiveness [1]

培训特邀深圳证券交易所相关领域专家授课，内容涵盖资本市场多个实务环节，构建起针对性强、专业性足的课程体系，强化参训人员专业认知与实操能 力。其中，科融通平台专家牛铭泽介绍上市板块选择、财务规范、法律合规及审核常见问题；法律事务部专家张超然介绍协议收购的合规流程、信披要求 及国资监管衔接及协议转让方式收购上市公司控股权注意事项；债券业务中心专家袁明系统讲解交易所固定收益产品，REITs、公司债、绿色债券、ABS 等产品的发行、审核与存续期管理；北方中心王世威对并购重组政策框架、重大资产重组认定标准、重组上市条件与程序，并结合实务案例解析操作路径 与风险防控要点。 此次培训是落实国企改革部署的重要举措，有效破解了参训人员在资本市场业务中的实操困惑，进一步深化了大家对资本市场运作规律的理解与把握，为 后续规范开展资本运作、创新融资模式、防范化解金融风险奠定了坚实基础。下一步，市国投集团将持续开展国企改革与资本运营专项培训，不断锤炼国 资系统队伍专业素养，为鄂尔多斯资本市场健康发展、区域经济转型升级注入强劲国资动能。 为进一步提升国有企业资本运作能力、资产证券化水平及资本市场合规意识，助力地方国有资本做优做强做大，1 ...

该国有企业于投资及基金管理方面拥有良好的往绩记录，并获深圳市国有企业集团的支持，该集团拥有 多元化的产业组合、强大的资源整合能力及丰富的资本市场运作经验。公司具备工业园区及仓储物业管 理、制造业相关服务、供应链金融及金融科技等核心能力，可提供稳固的产业平台。凭借集团多元化的 客户群，公司能够为该国有企业提供跨行业的宝贵见解及行业知识。 智通财经APP讯，朗华国际集团(08026)发布公告，于2026年1月29日，公司与一家国有投资公司(为深圳 市属国有企业的全资附属公司，"该国有企业")订立战略合作框架协议(框架协议)。根据框架协议，公司 与该国有企业拟建立长期战略关系，发挥彼等各自的行业及资本市场优势，共同物色主要聚焦于资本市 场的投资、并购及资本营运机会。 各订约方建议就(其中包括)确定和执行涉及先进工业和制造业的股权并购机会;设立及管理投资与并购基 金;及提供整合资本市场的解决方案，包括交易架构、融资及投资后价值赋能方面进行合作。 董事会相信，框架协议将支持集团的业务战略，善用其产业平台加强参与资本市场相关活动，加强行业 运作与投资及资本营运的整合，支持集团的长远增长及发展。 ...

2026年1月月15日日，由申万宏源证券担任独家主承销商的"山山东大大集控股集团有限公司 2026年面面向专业投资者非非公开发行行公司债券（第一一期）"成功发行行，本期债券发行行规 模10亿元，期限5年期，票面面利率2.70%。本期债券的发行行是山山东大大集控股集团在资 本市场的首首次亮相，全场认购倍数1.99倍，获得投资者的踊跃认购，充分体现了资本 市场对山山东大大集控股集团信用用水水平、综合实力力和发展前景的高高度认可，为山山东大大集控 股集团在资本市场良好运作、持续发展奠定坚实基础。 山山东大大集控股集团 是临沂市兰山山区重要的产业园区运营载体，自自组建以来围绕临 沂市物流、木木业、农业等特色色优势产业，以及临沂市木木业之都、物流之都、市场名 城、文文化名城、江北水水城、创新之城的发展目目标，承担了临沂市现代物流城一一系列产 业园区的开发运营工工作，包括智慧云仓、木木业科技众创园、中农财金金科技物流产业园 等，未来将发展成为以资产经营（产业园开发运营）为核心心，城市服务、金金融服务、 数字商贸为支支撑的 "一一体三翼"式综合性的产业控股集团。 本内容最终解释权归申万宏源证券有限公司所有。 免责声明 投资 ...

Core Insights - The report highlights the continuous expansion and improvement of the profitability of listed companies in Fujian Province, particularly in high-tech and advanced manufacturing sectors, supported by increased R&D investment and enhanced technological innovation capabilities [1][2]. Group 1: Company Performance - Fujian Province has a total of 228 listed companies, with 172 on the A-share market, including 68 on the Shanghai Stock Exchange (8 on the Sci-Tech Innovation Board) and 100 on the Shenzhen Stock Exchange (46 on the Growth Enterprise Market) [20]. - The overall scale of listed companies in Fujian is steadily increasing, with a notable rise in profitability, especially in high-tech industries [1]. - Companies are increasingly focusing on green and low-carbon transformations, emphasizing sustainable development and ESG practices [1]. Group 2: Market Dynamics - The activity level of Fujian's listed companies in the capital market is rising, with more diversified financing channels and a gradually improving multi-level capital market system [1]. - Some companies are demonstrating strong competitiveness in both domestic and international markets, with expanding brand influence [1]. Group 3: Regional Development - Core cities like Fuzhou and Xiamen remain the primary hubs for listed companies, while cities like Quanzhou and Zhangzhou are also seeing rapid growth in both the quantity and quality of enterprises, alleviating regional development imbalances [1]. Group 4: Resilience and Adaptability - Fujian's listed companies have shown strong resilience in responding to economic fluctuations and external risks, demonstrating good adaptability and pressure resistance [1].

Core Viewpoint - China Uranium Corporation, the controlling parent company of China Nuclear International, has officially listed on the Shenzhen Stock Exchange, which is expected to enhance the company's market position and strategic support for future development [1] Group 1: Company Overview - China Uranium Corporation indirectly holds approximately 66.72% of the issued shares of China Nuclear International [1] - The main business of China Uranium Corporation includes the mining, sales, and trading of natural uranium resources, as well as the comprehensive utilization and sales of radioactive co-associated mineral resources such as monazite and uranium-molybdenum [1] Group 2: Strategic Implications - The successful listing of China Uranium Corporation is anticipated to strengthen the synergy between the company and its parent, providing broader strategic support for future growth [1] - The company expects to benefit from the enhanced influence of its parent company in the capital market, which will positively impact brand recognition, resource integration, and strategic expansion [1]

Group 1 - The "Best State-owned Capital Institution" award selection is currently underway, organized by the China Listed Companies Industry Development Forum Committee, with broad attention from the capital market [2] - The selection process has completed nominations and preliminary reviews, now entering the online voting and self-recommendation phase, which ends on August 31 [3] - The evaluation aims to comprehensively review outstanding state-owned capital management and investment institutions that effectively utilize the capital market to enhance state capital efficiency and returns [3] Group 2 - The evaluation criteria are comprehensive, focusing not only on investment scale and capability but also on the ability to utilize capital market tools such as IPOs, mergers, reverse acquisitions, and refinancing [3] - The third China Listed Companies Industry Development Forum is the only high-end summit focusing on industrial development, supported by various institutions and will be held in Shanghai from September 20 to 22 [3][4] - The ongoing selection activity encourages state-owned institutions to actively participate and showcase their excellence in the capital market [4]

Policy Developments - Shanghai has initiated the online listing for the first batch of traditional Chinese medicine centralized procurement expansion, with the application period from August 12 to August 29, 2025 [1] Drug and Device Approvals - Hualan Vaccine has received approval for clinical trials of its lyophilized Hib conjugate vaccine, which is expected to induce immune response against Hib [2] - Insmed announced that the FDA has approved its first-in-class oral drug Brinsupri for treating non-cystic fibrosis bronchiectasis in patients aged 12 and older [3] - The National Medical Products Administration has received a market application for the intraocular injection of Bevacizumab from Fuhong Hanlin and Eddingpharm, marking the second such application in China [4] - Heng Rui Medicine has received approval for clinical trials of its innovative drug SHR-A2102 in combination with other treatments for recurrent/metastatic head and neck squamous cell carcinoma [5] Capital Market Activities - Inokang Medical Technology has started the listing guidance process with Huatai Securities, as disclosed by the China Securities Regulatory Commission [6] - Inokang was founded in 2014 by returnees and experienced professionals in the medical industry, and it has been recognized as a national high-tech enterprise [7] - Rejuve Bio announced a capital increase of 100 million yuan for its subsidiary ShunJing Biomedical Technology, with the company's stake decreasing from 45.5833% to 43.1842% [8] Industry Events - Zhifei Biological has completed the first nationwide vaccination of its quadrivalent influenza vaccine, highlighting the competitive landscape and market potential in China's influenza vaccine sector [10] - Zhonghui Bio's quadrivalent influenza vaccine has passed the preliminary review for inclusion in the national commercial health insurance innovative drug directory [11] - BeiGene anticipates that its drug Sotucumab will receive its first global approval by the end of 2026, with multiple milestone events expected soon [12] Public Sentiment Alerts - The re-registration application for Green Valley Pharmaceutical's mannitol sodium capsules has not been approved, indicating ongoing challenges for this controversial Alzheimer's drug [14] Shareholder Activities - Former Vice Chairman of Zhaoyan New Drug plans to reduce his holdings by up to 352.45 million shares due to personal financial needs, representing 0.4703% of the company's total share capital [15]

Core Viewpoint - The controversy surrounding GAC Aion's employee stock ownership plan has been exaggerated by some media outlets, leading to misinformation and damaging the brand's reputation, while highlighting the chaotic information dissemination in the current media landscape [1][15]. Group 1: Employee Stock Ownership Plan - The core issue of the employee stock ownership plan controversy lies in the malicious misinterpretation by some media outlets [2]. - GAC Aion's stock incentive plan has precedents, with a previous implementation in March 2023 covering 14% of employees and recognized as a benchmark case for state-owned enterprise reform [2]. - The company has clarified that the employee stock ownership plan is designed based on its development and capital market environment, and it is actively exploring various capital operation plans [2][4]. Group 2: Company Operations and Legal Actions - GAC Aion has stated that its operations are normal and that it has initiated legal actions against those spreading false rumors [4]. - The company has reported significant R&D investments, exceeding 7.9 billion yuan in 2024, with over 3,200 new patent applications [4]. - GAC Aion's solid-state battery research has entered the engineering prototype testing phase, achieving an energy density of over 400 Wh/kg, with plans for vehicle integration by 2026 [5]. Group 3: Market Position and Future Plans - GAC Aion is transitioning towards the consumer market, launching models like AION LX Plus and AION V Plus, while also planning to release new models in 2024 to enhance driving experience [6][7]. - The company has installed over 15,000 fast-charging stations across 202 cities in China, leading in charging network deployment [6]. - GAC Group aims to achieve a sales target of 2 million units for its self-owned brands by 2027, with GAC Aion playing a crucial role in this strategy [10]. Group 4: Financial Performance and Industry Challenges - GAC Group's total revenue for 2024 is projected to be approximately 106.79 billion yuan, reflecting a year-on-year decline of 17.05%, with a significant drop in net profit [13]. - The company faces dual pressures from declining sales in traditional joint venture brands and the competitive landscape of the new energy vehicle market [13]. - The ongoing challenges in the Chinese new energy vehicle market are exacerbated by external factors such as Tesla's upcoming Model 2 and new tariffs from the EU [13]. Group 5: Reform and Market Adaptation - GAC Aion's reform path represents a deep exploration of state-owned enterprises adapting to market competition, with various transformations since 2021 [14]. - The company has successfully attracted over 100 strategic investors during its A-round financing, indicating market confidence in its reform efforts [14]. - The narrative surrounding the controversy emphasizes the need for rational observation of reforms, as the company aims to enhance its value through stock incentives and strategic investments [14][16].

Group 1: Company Performance - The company achieved a revenue of 837 million CNY in 2024, representing a year-on-year growth of 42.77% [2] - The net profit for 2024 was 703.88 million CNY, reflecting a growth of 36.92% [2] Group 2: Overseas Production Capacity - The Vietnam production base successfully completed trial production in March 2025, with formal mass production expected to start in May 2025 [3] - The Vietnam base aims to mitigate market risks and enhance supply assurance for overseas markets [3] Group 3: Product Development and Sales Strategy - The company is expanding its product development team to diversify its product offerings beyond handheld electric tools [3] - Products developed by the new team will be sold through both self-owned brands online and a combination of self-owned and OEM models offline [3] Group 4: Market Strategy and Future Goals - The company plans to continue investing in electric tool R&D, focusing on differentiated and high-value products to enhance market competitiveness [4] - The goal for 2025 is to achieve a revenue target of 1.14 billion CNY, with a focus on increasing the sales proportion of lithium battery products, which accounted for 15.29% of sales in 2024, with a revenue growth of 93.94% [4]